Abstract
Ribotoxins constitute a family of toxic extracellular fungal RNases that exert a highly specific activity on a conserved region of the larger molecule of rRNA, known as the sarcin – ricin loop. This cleavage of a single phosphodiester bond inactivates the ribosome and leads to protein synthesis inhibition and cell death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid membranes in the absence of any known protein receptor. This ability is due to their capacity to interact with acid phospholipid-containing membranes. Both activities together explain their cytotoxic character, being rather specific when assayed against some transformed cell lines. The determination of high-resolution structures of some ribotoxins, the characterization of a large number of mutants, and the use of lipid model vesicles and transformed cell lines have been the tools used for the study of their mechanism of action at the molecular level. The present knowledge suggests that wild-type ribotoxins or some modified variants might be used in human therapies. Production of hypoallergenic mutants and immunotoxins designed against specific tumors stand out as feasible alternatives to treat some human pathology in the mid-term future.
Keywords: Asp f 1, fungal allergy, immunotoxin, restrictocin, Rnase, α-sarcin
Current Pharmaceutical Biotechnology
Title: The Therapeutic Potential of Fungal Ribotoxins
Volume: 9 Issue: 3
Author(s): Nelson Carreras-Sangra, Elisa Alvarez-Garcia, Elias Herrero-Galan, Jaime Tome, Javier Lacadena, Jorge Alegre-Cebollada, Mercedes Onaderra, Jose G. Gavilanes and Alvaro Martinez-del-Pozo
Affiliation:
Keywords: Asp f 1, fungal allergy, immunotoxin, restrictocin, Rnase, α-sarcin
Abstract: Ribotoxins constitute a family of toxic extracellular fungal RNases that exert a highly specific activity on a conserved region of the larger molecule of rRNA, known as the sarcin – ricin loop. This cleavage of a single phosphodiester bond inactivates the ribosome and leads to protein synthesis inhibition and cell death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid membranes in the absence of any known protein receptor. This ability is due to their capacity to interact with acid phospholipid-containing membranes. Both activities together explain their cytotoxic character, being rather specific when assayed against some transformed cell lines. The determination of high-resolution structures of some ribotoxins, the characterization of a large number of mutants, and the use of lipid model vesicles and transformed cell lines have been the tools used for the study of their mechanism of action at the molecular level. The present knowledge suggests that wild-type ribotoxins or some modified variants might be used in human therapies. Production of hypoallergenic mutants and immunotoxins designed against specific tumors stand out as feasible alternatives to treat some human pathology in the mid-term future.
Export Options
About this article
Cite this article as:
Carreras-Sangra Nelson, Alvarez-Garcia Elisa, Herrero-Galan Elias, Tome Jaime, Lacadena Javier, Alegre-Cebollada Jorge, Onaderra Mercedes, Gavilanes G. Jose and Martinez-del-Pozo Alvaro, The Therapeutic Potential of Fungal Ribotoxins, Current Pharmaceutical Biotechnology 2008; 9 (3) . https://dx.doi.org/10.2174/138920108784567335
DOI https://dx.doi.org/10.2174/138920108784567335 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melanoma
Current Cancer Therapy Reviews Active Targeted Drug Delivery for Microbes Using Nano-Carriers
Current Topics in Medicinal Chemistry Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Contribution of Specific Transport Systems to Anthracycline Transport in Tumor and Normal Cells
Current Drug Metabolism Recent Advances in Luminescent Carbon Dots
Current Analytical Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets The Renaissance of the 68Ge/68Ga Radionuclide Generator Initiates New Developments in 68Ga Radiopharmaceutical Chemistry
Current Topics in Medicinal Chemistry Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Development and Pharmacological Evaluation of a PEG Based Nanoparticulate Camptothecin Analog for Oral Administration
Current Drug Delivery Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Antiviral Properties of Quinolone-based Drugs
Current Drug Targets - Infectious Disorders Application of Nanotechnology in Miniaturized Systems and its Use for Advanced Analytics and Diagnostics – an Updated Review
Recent Patents on Food, Nutrition & Agriculture Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry